Meeting
2022 ASCO Annual Meeting
PD-L1 score as a prognostic biomarker in Asian patients with early-stage, EGFR-mutated lung cancer.
Authors
Stephanie Saw
National Cancer Centre Singapore, Singapore, Singapore
Stephanie Saw , Gillianne Lai , Aaron C. Tan , Siqin Zhou , Mei-Kim Ang , Wan-Teck Lim , Ravindran Kanesvaran , Wan Ling Tan , Tanujaa Rajasekaran , Johan Chan , Yi Lin Teh , Boon-Hean Ong , Angela M. Takano , Eng Huat Tan , Sze Huey Tan , Daniel Shao-Weng Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8527)
DOI
10.1200/JCO.2022.40.16_suppl.8527
Abstract #
8527
Poster Bd #
154
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2023 ASCO Annual Meeting
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
First Author: Jaume Capdevila
Poster
2018 ASCO Annual Meeting
Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).
First Author: Lee Chun Park
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans